5-O-Acetyl-Renieramycin T from Blue Sponge Xestospongia sp. Induces Lung Cancer Stem Cell Apoptosis.
A549 Cells
Animals
Antineoplastic Agents
/ chemistry
Apoptosis
/ drug effects
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cell Line, Tumor
Cisplatin
/ pharmacology
Humans
Lung Neoplasms
/ drug therapy
Neoplastic Stem Cells
/ drug effects
Signal Transduction
Tetrahydroisoquinolines
/ chemistry
Xestospongia
/ chemistry
5-O-acetyl-renieramycin T
Xestospongia sp.
anti-cancer
apoptosis
cisplatin
lung cancer
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
11 Feb 2019
11 Feb 2019
Historique:
received:
14
01
2019
revised:
06
02
2019
accepted:
07
02
2019
entrez:
14
2
2019
pubmed:
14
2
2019
medline:
30
5
2019
Statut:
epublish
Résumé
Lung cancer is one of the most significant cancers as it accounts for almost 1 in 5 cancer deaths worldwide, with an increasing incident rate. Management of the cancer has been shown to frequently fail due to the ability of the cancer cells to resist therapy as well as metastasis. Recent evidence has suggested that the poor response to the current treatment drugs and the ability to undergo metastasis are driven by cancer stem cells (CSCs) within the tumor. The discovery of novel compounds able to suppress CSCs and sensitize the chemotherapeutic response could be beneficial to the improvement of clinical outcomes. Herein, we report for the first time that 5-
Identifiants
pubmed: 30754694
pii: md17020109
doi: 10.3390/md17020109
pmc: PMC6409812
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Tetrahydroisoquinolines
0
renieramycin T
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Thailand Research Fund
ID : RSA6180036
Organisme : Japan Society for the Promotion of Science
ID : JP18K06561
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest in regard to this study. The authors alone are responsible for the content and writing of this article.
Références
J Biol Chem. 2000 Nov 17;275(46):35778-85
pubmed: 10958792
J Biol Chem. 2000 Dec 15;275(50):39435-43
pubmed: 10993883
Int J Cancer. 2002 Feb 10;97(5):584-92
pubmed: 11807782
Cell. 2002 Jan 25;108(2):153-64
pubmed: 11832206
Chem Rev. 2002 May;102(5):1669-730
pubmed: 11996547
J Nat Prod. 2003 Nov;66(11):1441-6
pubmed: 14640515
J Nat Prod. 2004 Jun;67(6):1023-8
pubmed: 15217287
Oncol Rep. 2004 Nov;12(5):955-65
pubmed: 15492778
Oncogene. 2007 Feb 26;26(9):1306-16
pubmed: 17322916
Annu Rev Cell Dev Biol. 2007;23:675-99
pubmed: 17645413
Int J Cancer. 2007 Dec 1;121(11):2387-94
pubmed: 17688235
PLoS One. 2008 Aug 27;3(8):e3077
pubmed: 18728788
Nat Rev Drug Discov. 2008 Dec;7(12):979-87
pubmed: 19043449
Nat Rev Drug Discov. 2009 Jan;8(1):69-85
pubmed: 19096380
Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):268-73
pubmed: 19116269
Chem Rev. 2009 Jul;109(7):3012-43
pubmed: 19422222
Bioorg Med Chem. 2009 Jul 1;17(13):4548-58
pubmed: 19457672
Int J Cancer. 2010 Feb 15;126(4):950-8
pubmed: 19676044
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6
pubmed: 19805294
Carcinogenesis. 2010 Aug;31(8):1376-80
pubmed: 20530554
Anticancer Res. 2010 Sep;30(9):3557-64
pubmed: 20944137
PLoS One. 2010 Nov 19;5(11):e14062
pubmed: 21124918
BMC Cancer. 2011 Feb 01;11:49
pubmed: 21284870
Genes Cancer. 2011 Mar;2(3):261-74
pubmed: 21779497
Oncogene. 2012 Apr 12;31(15):1869-83
pubmed: 21892204
J Pharmacol Sci. 2012;118(4):423-32
pubmed: 22466960
Hepatology. 2012 Sep;56(3):1004-14
pubmed: 22473773
Mol Cancer. 2012 Aug 13;11:54
pubmed: 22888789
Exp Oncol. 2012 Oct;34(3):165-75
pubmed: 23070001
Cancer Res. 2013 Jan 1;73(1):406-16
pubmed: 23135908
Int J Mol Med. 2013 Feb;31(2):315-24
pubmed: 23233126
PLoS One. 2013;8(1):e54193
pubmed: 23349823
Int J Clin Oncol. 2014 Apr;19(2):254-9
pubmed: 23479121
Cell Oncol (Dordr). 2013 Jul;36(4):265-75
pubmed: 23900738
Anticancer Res. 2013 Dec;33(12):5433-44
pubmed: 24324079
Oncogene. 2015 Feb 12;34(7):890-901
pubmed: 24561529
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Front Oncol. 2014 Oct 21;4:285
pubmed: 25374842
Anticancer Res. 2015 Sep;35(9):4585-92
pubmed: 26254346
Cancer Lett. 2016 Mar 28;372(2):147-56
pubmed: 26797015
J Org Chem. 2016 May 20;81(10):4039-47
pubmed: 27019081
Medicine (Baltimore). 2016 Sep;95(1 Suppl 1):S8-S19
pubmed: 27611937
Expert Opin Ther Pat. 2017 Jan;27(1):17-36
pubmed: 27623022
Pathol Int. 2017 Mar;67(3):121-130
pubmed: 28102575
Int J Oncol. 2017 Apr;50(4):1341-1351
pubmed: 28259926
Stem Cells Int. 2017;2017:2925869
pubmed: 28356914
Oncol Lett. 2017 Feb;13(2):1024-1030
pubmed: 28356995
Cell Death Dis. 2017 Apr 13;8(4):e2746
pubmed: 28406482
J Nat Prod. 2017 May 26;80(5):1541-1547
pubmed: 28459574
Anticancer Drugs. 2017 Nov;28(10):1141-1149
pubmed: 28885267
J Oral Maxillofac Pathol. 2017 Sep-Dec;21(3):463
pubmed: 29391738
J Biomed Sci. 2018 Mar 6;25(1):20
pubmed: 29506506
Oncol Lett. 2018 Apr;15(4):5627-5633
pubmed: 29552200
Stem Cells Int. 2018 Feb 28;2018:5416923
pubmed: 29681949
Oncol Lett. 2018 May;15(5):6791-6798
pubmed: 29731860
Anticancer Res. 2018 Jul;38(7):3797-3809
pubmed: 29970499
EMBO Rep. 2018 Sep;19(9):
pubmed: 29987135
ChemistryOpen. 2018 Aug 07;7(10):764-771
pubmed: 30338201